Hospitals & Diagnostics: Formalising India's Care Delivery
Rising incomes, insurance and lifestyle disease burden are driving formalisation of hospital and diagnostic care.
Market Size
~$100 Bn+ (India healthcare delivery, FY26E)
Growth
~12% CAGR (FY26–30E)
Read
7 min
Updated
Jul 2026
Overview
Healthcare delivery in India - hospitals, diagnostics and specialty care - is formalising as incomes rise, insurance penetration deepens and the burden of lifestyle and chronic diseases grows. Organised hospital chains are expanding capacity and clinical specialties, while diagnostic chains consolidate a highly fragmented market. Medical tourism adds an incremental, high-value demand pool.
Hospital economics turn on occupancy, average revenue per occupied bed (ARPOB), case mix and payer mix; scaling profitably requires clinical talent, brand and capital discipline. Diagnostics is scaling through networks, home-collection and asset-light franchising, with pricing pressure from digital-first disruptors. Insurance and government schemes (Ayushman Bharat) are widening the payer base.
The sector combines defensive demand with structural growth, but is capital-intensive (hospitals) and increasingly price-competitive (diagnostics). Brand, clinical outcomes and network density are the durable moats.
Illustrative projection from the report's stated market size (~$100 Bn+ (India healthcare delivery, FY26E)) and growth (~12% CAGR (FY26–30E)).
Key Highlights
- Formalisation of a largely unorganised care market
- ARPOB, occupancy and case mix drive hospital returns
- Diagnostics consolidating amid digital-first pricing pressure
- Insurance and Ayushman Bharat widening the payer base
Growth Drivers
- Rising incomes and health-insurance penetration
- Growing chronic and lifestyle disease burden
- Consolidation of fragmented diagnostics
- Medical tourism and specialty-care demand
Key Players
Investment Outlook
Healthcare delivery offers defensive, structurally growing demand, with hospitals rewarding capital-disciplined expansion and diagnostics rewarding scale and brand. We favour operators with strong ARPOB trends or network density and pricing power.
Key Risks
- Capital intensity and long gestation of new hospitals
- Pricing pressure and regulation in diagnostics
- Clinical-talent shortages and cost inflation
The Neoma View
We favour care-delivery franchises with brand strength and clinical outcomes; capital discipline in hospitals and network scale in diagnostics guide our selection.
Talk to an advisor →All figures are indicative and for information only - not investment advice or a recommendation. Market sizes, growth rates and financial metrics are hedged estimates that vary by source and period. Please consult your advisor before investing.
More in Healthcare
Pharma & CDMO
Pharma & CDMO: India as the World's Pharmacy and Contract Partner
Generics leadership plus a China+1 shift in contract manufacturing position Indian pharma for a structural upcycle.
Biotech
Biotech: Biosimilars, Vaccines and Novel Science
India's biotech strength in biosimilars and vaccines is broadening toward novel therapeutics and bio-services.
Digital Health
Digital Health: Tele-consultation, e-Pharmacy and Care Tech
e-Pharmacy, tele-consultation and health-tech platforms are digitising access to care across India.